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Objective. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with involvement of the upper and lower motor
neurons. Since the loss of ﬁne motor skills is one of the earliest signs of ALS, the hypothesis was tested if the nine hole PEG test
(NHPT) and transcranial magnet stimulation (TMS) with resting-motor threshold (RMT) could be useful in monitoring disease
progression. Methods. We examined 28 ALS patients and 27 age-matched healthy controls. ALS patients and healthy controls
underwent the nine hole peg test (NHPT) and TMS with RMT. Measurements in patients were repeated after three and
six months. Results. At baseline, the median NHPT durations were 1,4-fold longer (p< 0.001), and TMS scores showed a
signiﬁcant 0.8-fold smaller score in ALS patients compared with healthy controls (p< 0.001). 'e comparison of three and six
months versus baseline revealed signiﬁcant diﬀerences for NHPTdurations and ALSFRS-R in patients, whereas TMS scores did
not signiﬁcantly diﬀer in the patients. Conclusion. NHPT seems to be a good tool to evaluate dexterity of the hand and the
progression of the disease in ALS patients. TMS RMT to the hand muscles seems to be poorly qualiﬁed to evaluate the dexterity of
the hand function and the course of the disease.
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease with an involvement of upper and lower motor
neurons [1–3]. Consequently, patients can show atrophy and
paresis of the aﬀected muscles (lesion of the lower motor
neurons (LMNs)) and a loss of dexterity of the hands and
feet (lesion of the upper motor neurons (UMNs)). In-
volvement of the upper and lower motor neurons and pa-
tients with a primary involvement of the upper or lower
motor neurons can vary [1–3]. 'e nine hole peg test
(NHPT) was originally introduced by Kellor et al. in 1971 as
a measure of dexterity [4]. In 1985, detailed test instructions
and adult normative values according to hand, sex, and age
were provided [5]. Since 1988, the test is used as an upper
limb outcome measurement in multiple sclerosis, a disease
with an involvement of the corticospinal tract [6]. In the last
years, the NHPT could be assessed as a reliable test for
dexterity in other diseases of the central nervous system such
as stroke [7], traumatic brain injury [8], and cerebral palsy
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[9] but also for diseases with an involvement of the lower
motor neurons as peripheral neuropathies [10, 11]. Trans-
cranial magnetic stimulation (TMS) with resting-motor
threshold (RMT) is a tool to show the involvement of the
UMNs. In TMS studies, focal cortical changes and hyper-
excitability as a speciﬁc feature of ALS [12–16] could be
demonstrated. In the present study, NHPT and TMS with
RMT are assessed in a cohort of ALS patients and healthy
controls. Changes in these parameters over time and cor-
relation with disease severity are analyzed.
2. Materials and Methods
2.1. Patients and Control Subjects. In this study, 28 ALS
patients (mean age� 62.6 years, range� 48–84 years, 13
female, 15 male, 12 bulbar, 16 limb onset) were recruited.
Four of them had deﬁnite, nine probable, ten probable
laboratory-supported, and ﬁve possible ALS according to the
revised El Escorial criteria [17]. Twenty-seven age-matched
healthy controls (mean age� 63.5 years, range� 50–82 years,
13 female, 14male) were recruited.'ey had no prior history
of neurological disorders. All subjects (ALS patients and
healthy controls) underwent the NHPTand TMS, and RMT
was performed (see details below). 'e ALS patients and a
subgroup of ten healthy subjects (mean age� 62.3 years,
range� 55–72 years, ﬁve female, ﬁve male) underwent these
measurements after three and six months, respectively. 'e
ALS functional rating scale (ALSFRS-R, maximum score-
� 48) was used for all ALS patients to assess disease severity
at each measurement time point with lower scores repre-
senting more severe disability [18].
2.2. Nine Hole Peg Test (NHPT). 'e NHPT consists of a
board (wood) with 9 holes (10mm diameter and 15mm
depth) placed apart by 32mm and a container for the pegs, a
square box (100×100×10mm) apart from the board. 'e
participants were instructed to remove all the pegs from the
holes, one by one, and place them into the container and
then to take back the pegs from the container, one by one,
and replace them into the holes on the board, as quickly as
possible. 'e board should be placed at the client’s midline,
with the container holding the pegs oriented towards the
hand being tested. Only the hand being evaluated should
perform the test, and the hand not being evaluated is per-
mitted to hold the edge of the board in order to provide
stability. 'e scores are based on the time taken to complete
the test activity, recorded in seconds. To this end, a stop-
watch is utilized to record the time from the moment the
participant touches the ﬁrst peg until the moment the last
peg enters the last hole.
2.3. Transcranical Magnetic Stimulation (TMS) with Resting-
Motor;reshold (RMT). 'e focal TMS of the cortical hand
area of the left (L-M1) and right side (R-M1) was performed
using a Magstim-200 stimulator. It has a ﬁgure-of-eight coil
with external loop diameters of 90mm (Magstim Company,
Carmarthenshire, United Kingdom). It has also a mono-
phasic current waveform. During the stimulation, the
investigator performed the TMS tangentially to the skull.
'e handle was backward and laterally at a 45° angle to the
sagittal plane. By producing the largest TMS amplitudes
(stimulation of the hand areas elicited in the right and left
abductor pollicis brevis, respectively), the optimal coil po-
sitions were found. By using the relative frequency method
to the nearest 1% maximum stimulator output (MSO) [19],
the resting motor threshold (RMT) was determined. We
deﬁned it as the minimum intensity which could elicit a
motor evoked potential of >50 μV peak-to-peak amplitude
in at least 5 out of 10 subsequent trials. RMT is stated as
percentage of MSO.
2.4. Statistical Analysis. Statistical analysis of the data was
performed in R (a language and environment for statistical
computing, R Foundation for Statistical Computing,
Vienna, Austria. 2018). NHPT durations and TMS thresh-
olds were log-transformed before regression analysis, while
ALSFRS-R was analyzed on a normal scale as veriﬁed by
preliminary analysis of quantile comparison plots. Diﬀer-
ences between ALS patients and healthy controls were an-
alyzed by linear regression models. Changes over time were
evaluated using linear mixed-eﬀect models with baseline
values as reference. All regression models were adjusted for
age and gender.'e estimates of the eﬀect sizes derived from
the regressions were diﬀerence of mean values for ALSFRS
and back-transformed geometric mean ratios for NHPTand
TMS thresholds. In addition, the corresponding 95% con-
ﬁdence interval as well as the p value was indicated.
Correlations of NHPT duration and TMS scores, re-
spectively, with disease severity as assessed by the ALSFRS-R
were evaluated using Spearman’s rank correlation.
3. Results
Of the initial 28 ALS patients, eight were lost to follow-up:
two patients deceased after the baseline measurement, ﬁve
patients could not further participate in the study after a
rapid deterioration of their respiratory function, and one
patient withdrew willingness to participate in the study after
the initial measurement. 'us, longitudinal analysis of the
parameters was performed across 20 ALS patients (mean
age� 62.5 years, range� 48–84 years, 10 female, 10 male).
3.1. Patients and Controls. At the baseline, NHPT durations
were 1,4-fold longer (95% CI: 1.2, 1.7) in ALS patients
compared to healthy controls (p< 0.001, see Table 1). TMS
scores also signiﬁcantly diﬀered between ALS patients and
healthy controls: ALS patients showed a 0.8-fold smaller
score (95% CI: 0.65, 0.98, p � 0.031) than healthy patients.
In Table 2, median (range) values are indicated for NHPT
duration and TMS scores, while mean± SD are indicated for
ALSFRS-R over time. 'e comparison of three and six
months versus baseline by mixed-eﬀect models adjusted for
age and gender revealed signiﬁcant diﬀerences for NHPT
durations and ALSFRS-R in patients, whereas TMS scores
did not signiﬁcantly diﬀer. In the healthy controls, no sig-
niﬁcant changes were detected neither in the NHPT
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durations nor the TMS scores over time. Comparing the
relative eﬀect sizes of NHPTdurations and ALSFRS-R scores
in patients, NHPT showed a stronger eﬀect size than
ALSFRS-R scores, while NHPT values were 15% and 16%
larger after three and six months compared with baseline,
respectively, ALSFRS-R values were only about 5% and 10%
lower at the same time.
'ere was no signiﬁcant correlation between ALSFRS-R
and NHPT durations in the ALS patients, as assessed by
Spearman’s rank correlation (r� − 0.05, p � 0.66).
'ere was no signiﬁcant correlation between ALSFRS-R
and TMS scores in the ALS patients, as assessed by
Spearman’s rank correlation (r� 0.08, p � 0.55).
'ere was a highly signiﬁcant moderate negative cor-
relation between the NHPT durations and the ALFRS-R:
handwriting scores (r� − 0.53, p< 0.001).
'ere was no signiﬁcant correlation between the TMS
scores and the ALFRS-R: handwriting scores (r� 0.13,
p � 0.31).
4. Discussion
In this study, the NHPT durations and the TMS with RMT
scores in the disease progression of patients with ALS were
investigated. TMS with RMTstudies were performed earlier
with ALS patients [20, 21]. NHPT were only investigated in
an exploratory study with only one measurement and not
over time like in this study [22]. Also, both measurements
(TMS RMT and NHPT) were not combined before in a
study. NHPTduration is a reliable tool that has been used in
studies investigating diseases aﬀecting UMNs and LMNs for
years [6–11]. In this study, signiﬁcantly longer NHPT du-
rations were observed in patients compared with controls.
'is most likely mirrors the fact that in many patients,
impairment of dexterity is an early feature or will develop
during the course of the disease. 'is is supported by a
signiﬁcant change of NHPT durations in the ALS patient
over time. 'is suggests that the NHPT is a suitable tool to
evaluate dexterity and progression in ALS patients. 'is is in
line with previous studies of other diseases with involvement
of upper or lower motor neurons that indicate that the
NHPT is a suitable tool for patients with a primary in-
volvement of the UMNs and LMNs [6–11]. In our study, we
found a signiﬁcant diﬀerence between ALS patients com-
pared with controls using TMS. 'is result is in line in with
previous studies in which hyperexcitability could be detected
in ALS patients [12, 13, 20, 21, 23]. 'e development of
hyperexcitability in ALS is a well-known phenomenon and
develops during the early stages of the disease. In this study,
the cortical threshold, which is lower in ALS patients than in
controls, is the sign for hyperexcitability. It was reported to
be lowest early in the course of ALS and to subsequently
increase as the disease progresses [12, 20, 21, 23]. No sig-
niﬁcant changes of the TMS RMT scores over time were
observed in the present work. Maybe, the progression of
deterioration of the pyramidal tract in our patients was too
slow. Perhaps, this could be investigated in further studies.
But our results are in line with earlier ﬁndings that RMT
TMS is not as sensitive and speciﬁc as threshold tracking
TMS in ALS [13, 24].
5. Conclusion
NHPTseems to be a good tool to evaluate the dexterity of the
hand and the progression of the disease in ALS patients.
TMS with RMTto handmuscles seems to be poorly qualiﬁed
to objectively document the course of the disease and the
deterioration of the hand function.
Table 2: Mean values as well as standard deviations and median values as well as range, respectively, of the parameters for each group at
baseline as well as at three and six months.
Parameter Group
Mean± standard deviation/median (range)
Baseline 3 months 6 months
NHPT Patients 25 s (17–75 s) 28 s (18–130 s) 31 s (17–56 s)Controls 19.1± 2.8 s 20.0± 3.9 s 20.3± 2.7 s
TMS Patients 39.4%± 11.0% 38.9%± 10.5% 37.9%± 8.5%Controls 52.1%± 9.9% 52.2%± 8.4% 53.2%± 8.9%
ALSFRS-R Patients 39.8± 3.3 38.2± 3.8 36.5± 4.1Controls n.a. n.a. n.a.
n.a.: not applicable.
Table 1: Mean values as well as standard deviations and median values as well as range, respectively, of the parameters for patients and
controls at baseline. Log-transformed NHPT und TMS values were analysed by linear regression adjusted for age and gender. Geometric
mean ratios (GMR) and 95% CI and p value are indicated. Statistically signiﬁcant values are designated by an asterisk.
Parameter
Mean± standard deviation/median (range)
Patients Controls GMR (95% CI)
NHPT 24 s (16–75 s) 19 s (15–28 s) 1.41 (1.20, 1.66)
TMS 42% (34.5–46.5%) 52% (47–60%) 0.80 (0.65, 0.98)
ALSFRS 40.2± 3.1 n.a. n.a.
n.a.: not applicable.
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Abbreviations
ALS: Amyotrophic lateral sclerosis
ALSFRS-R: Amyotrophic lateral sclerosis functional rating
scale revised
APB: Abductor pollicis brevis muscle
MSO: Maximum stimulator output
NHPT: Nine hole PEG test
RMT: Resting-motor threshold
TMS: Transcranial magnet stimulation.
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